Prostaglandin analogs are an important therapeutic agents used in treating glaucoma. This increasingly common disease manifests itself inter alia by increased intraocular pressure. Consequently, it causes irreversible degenerative changes in the visual organ, hence importance of efficacious pharmacological treatment. Research towards development of a formulation process for generic prostaglandin eye drops will be presented on the example of travoprost. Typical hurdles of the process development involving prostaglandin are: low dose of the active substance, difficulties connected with dissolving it in the target formulation and obtaining a homogenous solution. The result of  experiments demonstrating significance of various factors used in the process elaboration to select the most effective way of transferring the active pharmaceutical ingredient to the final form of preparation, while avoiding the content loss and creation of impurities, will be presented. As a result of conducted research, product specification fulfilling the requirements imposed by pharmacopoeia, and documenting suitable stability, was established.

Project is co-financed by European Union, POIG no. UDA-POIG.01.03.01-14-068.

• Legal notice:
  

  Copyright (c) Pielaszek Research, all rights reserved.
  The above materials, including auxiliary resources, are subject to Publisher's copyright and the Author(s) intellectual rights. Without limiting Author(s) rights under respective Copyright Transfer Agreement, no part of the above documents may be reproduced without the express written permission of Pielaszek Research, the Publisher. Express permission from the Author(s) is required to use the above materials for academic purposes, such as lectures or scientific presentations.
  In every case, proper references including Author(s) name(s) and URL of this webpage: https://science24.com/paper/31185 must be provided.

1. Manufacturing of modified release tablets
2. A novel convergent synthesis of the prostaglandin F_2α analogues
3. Comparative permeation studies of tacalcitol through the human skin from brand product versus generic product
4. HPLC method for determination of the enantiomeric purity of a new ω chain aldehyde synthon used in the synthesis of travoprost
5. Experimental and theoretical charge density studies on a model analogue of vitamin D
6. The development of the spectrofotometric and HPLC method for studying enteric coated capsules containing Duloxetine Hydrochloride active substance
7. Development of RP HPLC method for the analysis of calcipotriol in cream and ointment
8. A novel synthesis of 19-nor analogs of vitamin D
9. New rosiglitazone salts
10. High-yielded method of synthesis of voriconazole.
11. ANTIPROLIFERATIVE ACTIVITY IN VITRO OF DIASTEREOMERIC ANALOGUES OF VITAMIN D3 AGAINST NORMAL AND CANCER CELL LINES